TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET 25
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26
2 MARKET SEGMENTATION 29
2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 DBMR TRIPOD DATA VALIDATION MODEL 32
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.6 MULTIVARIATE MODELLING 36
2.7 PRODUCT LIFELINE CURVE 36
2.8 DBMR MARKET POSITION GRID 37
2.9 VENDOR SHARE ANALYSIS 38
2.10 SECONDARY SOURCES 39
2.11 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 MARKET OVERVIEW 45
4.1 DRIVERS 47
4.1.1 INCREASE IN THE GERIATRIC POPULATION 47
4.1.2 RISING INCIDENCE OF GLAUCOMA ACROSS THE WORLD 47
4.1.3 GOVERNMENT INITIATIVES TO INCREASE AWARENESS ABOUT PREVENTION OF BLINDNESS 48
4.1.4 GROWING POPULARITY OF MINIMALLY INVASIVE SURGERY ACROSS THE GLOBE 48
4.2 RESTRAINTS 49
4.2.1 INADEQUATE REIMBURSEMENT SCENARIO 49
4.2.2 STRINGENT REGULATIONS FOR MIGS DEVICES 49
4.2.3 HIGH COST OF SURGICAL PROCEDURES 50
4.3 OPPORTUNITIES 50
4.3.1 RAPID TRANSITION FROM GLAUCOMA MEDICATION TO MINIMALLY INVASIVE GLAUCOMA SURGERIES 50
4.3.2 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCT 50
?
4.4 CHALLENGES 52
4.4.1 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE 52
4.4.2 RISKS ASSOCIATED WITH THE MICRO INVASIVE GLAUCOMA SURGERY 52
5 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY PRODUCT 53
5.1 OVERVIEW 54
5.2 MIGS STENTS 56
5.3 MIGS SHUNTS 56
5.4 OTHERS 57
6 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY TARGET 58
6.1 OVERVIEW 59
6.2 TRABECULAR MESHWORK 62
6.3 SUPRACHOROIDAL SPACE 62
6.4 SUBCONJUNCTIVAL FILTRATION 62
6.5 REDUCING AQUEOUS PRODUCTION 63
7 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY SURGERY TYPE 64
7.1 OVERVIEW 65
7.2 GLAUCOMA IN CONJUNCTION WITH CATARACT 67
7.3 STAND-ALONE GLAUCOMA 68
8 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY END USER 69
8.1 OVERVIEW 70
8.2 HOSPITAL OUTPATIENT DEPARTMENTS (HOPD) 72
8.3 OPHTHALMOLOGY CLINICS 73
8.4 AMBULATORY SURGERY CENTERS (ASCS) 73
8.5 OTHERS 74
9 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY DISTRIBUTION CHANNEL 75
9.1 OVERVIEW 76
9.2 DIRECT TENDER 78
9.3 RETAIL SALES 78
10 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY GEOGRAPHY 79
10.1 OVERVIEW 80
10.2 NORTH AMERICA 85
10.2.1 U.S. 90
10.2.2 CANADA 92
10.2.3 MEXICO 94
10.3 EUROPE 96
10.3.1 GERMANY 101
10.3.2 FRANCE 103
10.3.3 U.K. 105
10.3.4 ITALY 107
10.3.5 SPAIN 109
10.3.6 SWITZERLAND 111
10.3.7 NETHERLANDS 113
10.3.8 BELGIUM 115
10.3.9 RUSSIA 117
10.3.10 TURKEY 119
10.3.11 REST OF EUROPE 121
10.4 ASIA-PACIFIC 122
10.4.1 CHINA 127
10.4.2 JAPAN 129
10.4.3 INDIA 131
10.4.4 SOUTH KOREA 133
10.4.5 AUSTRALIA 135
10.4.6 SINGAPORE 137
10.4.7 THAILAND 139
10.4.8 MALAYSIA 141
10.4.9 INDONESIA 143
10.4.10 PHILIPPINES 145
10.4.11 REST OF ASIA-PACIFIC 147
10.5 SOUTH AMERICA 148
10.5.1 BRAZIL 153
10.5.2 ARGENTINA 155
10.5.3 REST OF SOUTH AMERICA 157
10.6 MIDDLE EAST AND AFRICA 158
10.6.1 SOUTH AFRICA 163
10.6.2 SAUDI ARABIA 165
10.6.3 U.A.E. 167
10.6.4 ISRAEL 169
10.6.5 EGYPT 171
10.6.6 REST OF MIDDLE EAST AND AFRICA 173
11 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, COMPANY LANDSCAPE 174
11.1 COMPANY SHARE ANALYSIS: GLOBAL 174
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 175
11.3 COMPANY SHARE ANALYSIS: EUROPE 176
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 177
12 COMPANY PROFILE 178
12.1 GLAUKOS CORPORATION 178
12.1.1 COMPANY SNAPSHOT 178
12.1.2 REVENUE ANALYSIS 178
12.1.3 COMPANY SHARE ANALYSIS 179
12.1.4 PRODUCT PORTFOLIO 179
12.1.5 RECENT DEVELOPMENTS 179
12.2 ALLERGAN 180
12.2.1 COMPANY SNAPSHOT 180
12.2.2 REVENUE ANALYSIS 181
12.2.3 COMPANY SHARE ANALYSIS 181
12.2.4 PRODUCT PORTFOLIO 182
12.2.5 RECENT DEVELOPMENT 182
12.3 IVANTIS, INC. 183
12.3.1 COMPANY SNAPSHOT 183
12.3.2 COMPANY SHARE ANALYISIS 183
12.3.3 PRODUCT PORTFOLIO 183
12.3.4 RECENT DEVELOPMENTS 184
12.4 ELLEX 185
12.4.1 COMPANY SNAPSHOT 185
12.4.2 REVENUE ANALYSIS 186
12.4.3 COMPANY SHARE ANALYSIS 186
12.4.4 PRODUCT PORTFOLIO 187
12.4.5 RECENT DEVELOPMENT 187
12.5 ALCON 188
12.5.1 COMPANY SNAPSHOT 188
12.5.2 REVENUE ANALYSIS 189
12.5.3 PRODUCT PORTFOLIO 189
12.5.4 RECENT DEVELOPMENT 189
12.6 BVI 190
12.6.1 COMPANY SNAPSHOT 190
12.6.2 PRODUCT PORTFOLIO 190
12.6.3 RECENT DEVELOPMENT 190
12.7 JOHNSON & JOHNSON SURGICAL VISION, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 191
12.7.1 COMPANY SNAPSHOT 191
12.7.2 REVENUE ANALYSIS 191
12.7.3 PRODUCT PORTFOLIO 192
12.7.4 RECENT DEVELOPMENT 192
12.8 MICROSURGICAL TECHNOLOGY (A SUBSIDIARY OF HALMA PLC) 193
12.8.1 COMPANY SNAPSHOT 193
12.8.2 REVENUE ANALYSIS 193
12.8.3 PRODUCT PORTFOLIO 194
12.8.4 RECENT DEVELOPMENTS 194
12.9 MOLTENO OPHTHALMIC LTD 195
12.9.1 COMPANY SNAPSHOT 195
12.9.2 PRODUCT PORTFOLIO 195
12.9.3 RECENT DEVELOPMENT 195
12.10 NEW WORLD MEDICAL, INC. 196
12.10.1 COMPANY SNAPSHOT 196
12.10.2 PRODUCT PORTFOLIO 196
12.10.3 RECENT DEVELOPMENT 196
12.11 SANTEN PHARMACEUTICAL CO., LTD. 197
12.11.1 COMPANY SNAPSHOT 197
12.11.2 REVENUE ANALYSIS 197
12.11.3 TECHNOLOGY PORTFOLIO 198
12.11.4 RECENT DEVELOPMENT 198
12.12 SIGHT SCIENCES 199
12.12.1 COMPANY SNAPSHOT 199
12.12.2 PRODUCT PORTFOLIO 199
12.12.3 RECENT DEVELOPMENT 199
13 SWOT & DATA BRIDGE MARKET RESEARCH ANALYSIS 200
13.1 SWOT: ANALYSIS 200
13.1.1 STRENGTH: - STRONG GLOBAL PRESENCE 200
13.1.2 WEAKNESS: - DEPENDENCE ON THIRD PARTY SUPPLIERS/CONTRACTORS 200
13.1.3 OPPORTUNITIES: - INCREASED RESEARCH AND DEVELOPMENT ACTIVITIES 201
13.1.4 THREAT: - FOREIGN CURRENCY CONVERSION RISKS 201
13.2 DATA BRIDGE MARKET RESEARCH ANALYSIS 201
14 CONCLUSION 202
15 QUESTIONNAIRE 203
16 RELATED REPORTS 206